Abaloparatide
Also known as: Tymlos, BA058
Key Facts: Abaloparatide
- Category
- Hormonal
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - Postmenopausal osteoporosis
- Administration
- Subcutaneous injection daily
- Typical Dose
- 80 mcg daily
- Frequency
- Once daily
- Evidence Level
- FDA Approved
- Duration
- Maximum 2 years (same lifetime limit as teriparatide)
What to Expect
A PTHrP analog that stimulates bone formation with potentially fewer side effects than teriparatide. Newer anabolic option for osteoporosis.
Mechanism of Action
Abaloparatide is an analog of PTH-related protein (PTHrP). It preferentially binds to the RG conformation of PTH1 receptor, favoring anabolic signaling over bone resorption. Results in bone building with less hypercalcemia.
Research Summary
ACTIVE trial showed superior reduction in vertebral and non-vertebral fractures vs placebo. Comparative data suggests similar or better efficacy than teriparatide with less hypercalcemia. Second anabolic osteoporosis drug approved.
Dosing Information
Typical Dosingⓘ
Community experience
80 mcg daily
80 mcg daily
Once daily
PTHrP analog for osteoporosis. Similar to teriparatide but different binding profile.
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
80 mcg subcutaneous daily
Duration
Maximum 2 years (same lifetime limit as teriparatide)
Administration
Subcutaneous injection daily
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Hypercalciuria (11%)
- ●Dizziness (10%)
- ●Nausea (8%)
- ●Palpitations (5%)
- ●Injection site reactions
- ●Orthostatic hypotension
- ●Osteosarcoma risk in rats
- ●FDA approved (Tymlos)
References
Related Peptides
Peptides commonly compared with Abaloparatide or used in similar applications.
Oxytocin
FDAA naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.
HormonalGonadorelin
FDAA synthetic version of gonadotropin-releasing hormone. Used diagnostically and therapeutically for various reproductive and hormonal conditions.
HormonalLeuprolide
FDAA GnRH agonist that suppresses testosterone and estrogen production. FDA approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty.
HormonalDesmopressin
FDAA synthetic analog of vasopressin (ADH) used for diabetes insipidus, bedwetting, and bleeding disorders. Does not cause vasoconstriction like natural vasopressin.
HormonalOctreotide
FDAA synthetic somatostatin analog that inhibits multiple hormones. Used for acromegaly, carcinoid tumors, and various GI conditions.
HormonalLanreotide
FDAA long-acting somatostatin analog similar to octreotide. FDA approved for acromegaly and gastroenteropancreatic neuroendocrine tumors.
HormonalWant updates on Abaloparatide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.